Clinical study to compare overall survival (OS) in patients with platinumsensitive recurrent ovarian cancer with a positive AGO-score randomized to tumor debulking surgery followed by chemotherapy of physician’s choice versus chemotherapy of physician’s choice alone
Sponsor: Philipps-University Marburg
SEEK ID: https://ldh.kks-marburg.imise.uni-leipzig.de/projects/6
Public web page: Not specified
NFDI4Health PIs: No PIs for this Trial Project
Trial Project start date: 14th Jul 2010
Trial Project end date: 17th Jan 2020
- : Study
- : A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
- : English
- : AGO-OVAR OP.4 (Desktop III)
- : English
- : Clinical study to compare overall survival (OS) in patients with platinumsensitive recurrent ovarian cancer with a positive AGO-score randomized to tumor debulking surgery followed by chemotherapy of physician’s choice versus chemotherapy of physician’s choice alone
- : English
- : overall survival
- : platinumsensitive recurrent ovarian cancer
- : tumor debulking
- : Organisational
- Details about the contributing organisation(s)/institution(s)/group(s)
- : Sponsor (primary)
- : Not specified
- : Philipps-University Marburg
- Details about the contributing person(s)
- : Not specified
- : Not specified
- : Not specified
- Digital identifier(s)
- : Not specified
- : Not specified
- : info@kks.uni-marburg.de
- : Not specified
- Organisation(s) associated with the contributor
- : Philipps-University Marburg/KKS
- : Karl-von-Frisch-Str. 4, 35043 Marburg
- : https://www.kks.uni-marburg.de
- Digital identifier(s)
- : Not specified
- : Not specified
- : NCT (ClinicalTrials.gov)
- : NCT0116673
- : Interventional
- Specification of the type of the Project
- : Parallel
- : []
- Primary health condition(s) or disease(s) considered in the Project
- : Recurrent Ovarian Cancer
- : ICD-10
- : Not specified
- Groups of diseases or conditions(*)
- : Neoplasms (II)
- : []
- : Not specified
- Administrative information about the Project
- : Request for approval submitted, approval granted
- : Completed: Recruitment, data collection, and data quality management completed normally
- : No
- : 14 July 2010
- : 17 January 2020
- : Multicentric
- : 42
- : Not specified
- : Not specified
- : Person
- Eligibility criteria for Project participants
- Eligibility criteria: Minimum age
- : 18
- : Years
- Eligibility criteria: Maximum age
- : 99
- : Years
- : Female
- : see protocol
- : see protocol
- Population of the Project(*)
- : National
- : Germany
- : nationwide
- Interventions of the Project
- : Maximum effort cytoreductive surgery with subsequent systemic therapy on physician's choice
- : Procedure/Surgery
- : Not specified
- : Experimental
- Exposures of the Project
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- Outcome measures in the Project
- : Overall Survival (OS)
- : Not specified
- : Primary
- : up to 72 months after start of the trial
- : Not specified
- : []
- Data sharing strategy of the Project(*)
- : Undecided, it is not yet known if data will be made available
- : []
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- Non-interventional aspects of the Project
- : []
- Target follow-up duration of the Project
- : Not specified
- : Not specified
- : Not specified
- : []
- : Not specified
- Interventional aspects of the Project
- : Not applicable
- Masking of intervention(s) assignment
- : Not specified
- : []
- : Not specified
- : Randomized
- : Not specified
Related items
Trial Projects:
- Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION)
- Lymphadenectomy in Ovarian Neoplasms (LION)
- Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-pem)
- A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
- Efficacy and Safety of Pegylated-Proline-Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients with Chronic Myeloid Leukemia (CML) who Discontinue ABL-Kinase Inhibitor Therapy
- A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA
Institutions: Philipps-University Marburg, Coordinating Center for Clinical Trials

Trial Projects:
- Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION)
- Lymphadenectomy in Ovarian Neoplasms (LION)
- Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-pem)
- A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA
- A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
- Efficacy and Safety of Pegylated-Proline-Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients with Chronic Myeloid Leukemia (CML) who Discontinue ABL-Kinase Inhibitor Therapy
Web page: Not specified
Abstract (Expand)
Authors: P. Harter, J. Sehouli, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, B. J. Mosgaard, F. Selle, F. Guyon, C. Pomel, F. Lecuru, R. Zang, E. Avall-Lundqvist, J. W. Kim, J. Ponce, F. Raspagliesi, G. Kristensen, J. M. Classe, P. Hillemanns, P. Jensen, A. Hasenburg, S. Ghaem-Maghami, M. R. Mirza, B. Lund, A. Reinthaller, A. Santaballa, A. Olaitan, F. Hilpert, A. du Bois
Date Published: 2nd Dec 2021
Publication Type: Journal
PubMed ID: 34874631
Citation: N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294.
Creator: Gerrit zur Hausen
Submitter: Gerrit zur Hausen